Edelson Lechtzin LLP Launches Investigation into Ventyx Biosciences for Securities Violations

Edelson Lechtzin LLP Investigates Ventyx Biosciences

Edelson Lechtzin LLP has officially announced an investigation into Ventyx Biosciences, Inc. (NASDAQ: VTYX), focusing on potential violations of federal securities laws. This is a significant development for investors and stakeholders involved with Ventyx, especially in light of recent allegations related to misleading business information disseminated to the public.

Background on Ventyx Biosciences

Ventyx Biosciences is a clinical-stage biopharmaceutical company specializing in developing oral therapies that target autoimmune, inflammatory, and neurodegenerative diseases. The company aims to address critical health challenges with innovative treatments, but recent developments have raised concerns among investors and analysts alike.

Allegations and Their Implications

On December 2, 2025, Ventyx announced a delay in reporting the topline results of its Phase 2 trial for VTX2735, aimed at treating recurrent pericarditis. The company's CEO disclosed that this postponement was necessary to test a new formulation for daily use and to expand the study into multiple regions, including Canada, the EU, and the UK. However, this announcement had an immediate adverse effect, causing Ventyx's stock to plummet by $1.44 per share, a reduction representing approximately 15.35%, closing at a mere $7.94 per share that day.

This decline raised alarms, prompting concerns about transparency and the potential for market manipulation or misinformation. Investors who believe they have been adversely affected by these developments are encouraged to reach out to Edelson Lechtzin LLP for assistance.

Call to Action for Affected Investors

Edelson Lechtzin's lead attorney, Eric Lechtzin, stresses the importance of gathering information from affected investors, as well as witnesses who might illuminate the situation. The law firm's notification is a proactive step encouraging those who suffered losses related to Ventyx's stock to come forward. Investors can contact the firm directly at 844-563-5550 or via email.

About Edelson Lechtzin LLP

Edelson Lechtzin LLP is recognized as a national class action law firm based in Pennsylvania and California. The firm specializes not only in securities and investment fraud cases but also tackles various legal issues, including antitrust laws, employee benefit plans under ERISA, and consumer fraud. Their focus on class and collective litigation highlights their commitment to protecting the rights of investors and consumers alike.

Contact Information

For more information about the investigation or to provide relevant information, interested parties may contact:

Eric Lechtzin, Esq.
EDELSON LECHTZIN LLP
411 S. State Street, Suite N-300
Newtown, PA 18940
Phone: 844-696-7492 ext. 1
Email: [email protected]
Website: edelson-law.com

This announcement serves as a reminder that investors should remain vigilant about the companies in which they invest and stay informed regarding any potential legal challenges that may affect their portfolios. Investors related to Ventyx should act swiftly to protect their interests and seek the necessary legal counsel if they suspect wrongdoing or have experienced significant losses.